MedeliX
Start asking

Zolmitriptan

Aurasin Akut Stada, Zolmitriptan, Zomig · ATC code N02CC03

Brand names: Aurasin Akut Stada, Zomig, Ascotop, Gravis, Migtera, zolmiptriptan

Key facts
Active substance
Zolmitriptan
Drug class
Antimigraine
ATC code
N02CC03
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Zolmitriptan is a triptan (serotonin 5-HT1B/1D agonist). Per the US prescribing information, the tablets are used for the acute treatment of migraine with or without aura in adults.

What it is used for

  • Acute treatment of migraine with or without aura in adults, once a clear diagnosis is established
  • Not for migraine prevention; not established for cluster headache

Dosing

  • Starting dose 1.25 mg or 2.5 mg; maximum single dose 5 mg
  • If the migraine persists or returns, a second dose may be taken at least 2 hours after the first; maximum 10 mg in any 24-hour period
  • Safety of treating more than three migraines on average in 30 days is not established
  • Moderate to severe hepatic impairment: 1.25 mg; severe hepatic impairment: no more than 5 mg per day
  • With cimetidine: maximum single dose 2.5 mg, not more than 5 mg in 24 hours

Contraindications

  • Ischemic coronary artery disease, other significant cardiovascular disease, or coronary vasospasm including Prinzmetal's angina
  • Wolff-Parkinson-White syndrome or other accessory pathway arrhythmias
  • History of stroke, TIA, or hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension
  • Use within 24 hours of another triptan or ergot-type drug; use with MAO-A inhibitors; hypersensitivity

Important warnings

  • Myocardial ischemia, myocardial infarction and Prinzmetal angina; cardiovascular evaluation in patients with multiple risk factors before first use
  • Arrhythmias; chest, throat, neck and jaw pain/tightness/pressure
  • Cerebrovascular events and other vasospasm reactions
  • Medication overuse headache
  • Serotonin syndrome; increase in blood pressure

Side effects

  • Most common (≥ 5% and more than placebo): neck/throat/jaw pain, dizziness, paresthesia, asthenia, somnolence, warm/cold sensation, nausea, heaviness sensation, dry mouth
  • Serious: myocardial infarction, arrhythmias, stroke, serotonin syndrome

Interactions

  • Ergot-containing drugs and other triptans: not within 24 hours
  • MAO-A inhibitors: contraindicated
  • SSRIs and SNRIs: serotonin syndrome has been reported
  • Cimetidine: zolmitriptan levels approximately doubled – dose limit

Pregnancy and breastfeeding

  • No adequate data in pregnant women; animal studies showed embryolethality and fetal abnormalities at clinically relevant exposures
  • No data on passage into human milk

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Austria

  • Aurasin Akut StadaStada Arzneimittel Gmbh · 1 register entry
  • Zolmitriptan1a Pharma Gmbh, Sandoz Gmbh, Stada Arzneimittel Gmbh · 3 register entries
  • ZomigGrünenthal Österreich Gmbh · 3 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • AscotopGrünenthal Gmbh · 2 register entries
  • Zolmitriptan1 A Pharma Gmbh, Neuraxpharm Arzneimittel Gmbh, Glenmark Arzneimittel Gmbh, Hexal Ag, Stadapharm Gmbh, Viatris Germany Gmbh, Aliud Pharma Gmbh · 7 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • GravisSANOVEL İLAÇ SAN. VE TİC. A.Ş. · 4 register entries
  • MigteraNOBEL İLAÇ SAN. VE TİC. A.Ş. · 5 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

USA

  • zolmiptriptanGlenmark Pharmaceuticals Inc., USA · 1 register entry
  • ZomigAmneal Pharmaceuticals LLC · 1 register entry

Source: U.S. FDA – Drug labels (openFDA/DailyMed), as of 2026-10-29

Brand names in 16 more European countries
Belgium
Zolmitriptan-Instant Ab, Zolmitriptan Instant Eg, Zolmitriptan Odis Viatris, Zolmitriptan Sandoz, Zolmitriptan Viatris, Zolmitriptan‐instant Ab, Zomig
Croatia
Zelmykra, Zomig
Cyprus
Zomig
Czechia
Zolmitriptan Teva
Denmark
Zolmitriptan Holsten, Zolmitriptan Stada, Zolmitriptan ”holsten”, Zomig Nasal
Finland
Zolmistad, Zolmitriptan Sandoz, Zolmitriptan Stada, Zomig
France
Zolmitriptan Arrow Generiques, Zolmitriptan Biogaran, Zolmitriptan Cristers, Zolmitriptan Eg, Zolmitriptan Evolugen, Zolmitriptan La Colina, Zolmitriptan Sandoz, Zolmitriptan Teva Sante, Zolmitriptan Viatris, Zolmitriptan Zentiva, Zolmitriptan Zydus France, Zomig, Zomigoro
Ireland
Zolmitriptan Accord Healthcare Ireland, Zomig
Italy
Headzol, Zolmitriptan Aurobindo, Zolmitriptan Doc Generici, Zomig
Luxembourg
Zolmitriptan Instant Eg, Zolmitriptan Viatris, Zomig
Netherlands
Zolmitriptan Disper Aurobindo, Zolmitriptan Glenmark, Zolmitriptan Jubilant, Zolmitriptan Sandoz, Zolmitriptan Viatris, Zomig
Norway
Zolmitriptan Sandoz, Zomig
Poland
Zolmiles
Portugal
Zolmitriptano Aurovitas, Zolmitriptano Ciclum, Zolmitriptano Generis Phar, Zolmitriptano Vitória, Zolmitriptano Zentiva, Zomig
Spain
Zolmitriptán Flas Cinfa, Zolmitriptán Flas Combix, Zolmitriptán Flas Qualigen, Zolmitriptán Flas Stada, Zolmitriptán Flas Teva-Ratio, Zolmitriptán Normon, Zolmitriptán Sandoz, Zolmitriptán Viso Farmacéutica, Zomig
Sweden
Zolmitriptan, Zomig

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Zolmitriptan (BluePoint Laboratories) – Prescribing Information, 2026-04-16. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6628b7a-0b63-4e6f-a5e7-2fa195265235
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. U.S. FDA – Drug labels (openFDA/DailyMed), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/
  6. Wikidata (CC0): ATC N02CC.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.